Digestive wellness encompasses a wide range of needs—from everyday comfort to nutritional support for people living with persistent gut conditions. Within this landscape, inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) deserve distinct attention.
The CDC estimates that 2.4–3.1 million people in the United States live with IBD. Separately, the Rome Foundation’s global epidemiology study found that 4.1% of adults surveyed online met Rome IV diagnostic criteria for IBS. [1,2]
These figures highlight an important opportunity: developing more targeted, evidence-backed dietary support for people with fragile or disrupted gut environments.
IBD and IBS: Different Conditions, Distinct Needs
IBD includes ulcerative colitis (UC) and Crohn’s disease—chronic inflammatory conditions that can damage the digestive tract. IBS, by contrast, is characterized by recurring abdominal pain and changes in bowel habits without the structural tissue damage associated with IBD.
This distinction matters both clinically and commercially. Many digestive-health products are designed for broad, everyday wellness and often focus on one or a few individual probiotic strains. However, people with fragile or disrupted gut environments may be looking for a more targeted approach—one that considers the wider microbial ecosystem and can be responsibly positioned alongside appropriate medical care.
For brands, this creates an opportunity to move beyond one-size-fits-all digestive support and develop differentiated solutions for condition-aware, fragile-gut audiences.
RESET Microbiome: Focusing on the Gut Environment
With Symbiota™ 020, MICROBIO’s RESET Microbiome approach focuses on the gut microenvironment and the resident microbial community.
Produced through true multi-strain co-fermentation, Symbiota™ 020 delivers fermentation-derived metabolites without requiring live-cell survival or colonization. This approach looks beyond adding individual microorganisms to consider the conditions in which the gut ecosystem functions.
Clinical Research in Ulcerative Colitis
Research in ulcerative colitis, a form of IBD, examined Symbiota™ 020 alongside existing medication. The reported results compared Symbiota™ 020 plus existing medication with placebo plus existing medication:
| Clinical Remission Rate | Symptom Remission Rate | ||
| Treatment | 4 weeks | 12 weeks | 12 weeks |
| Symbiota™ 020 + Existing Medication | 58.3% | 83.3% | 91.7% |
| Placebo + Existing Medication | 7.1% | 35.7% | 50.0% |
The reported differences in clinical remission were 51.2 percentage points at four weeks and 47.6 percentage points at twelve weeks. At twelve weeks, the difference in symptom remission was 41.7 percentage points.
These findings offer encouraging evidence for application of Symbiota™ 020 as complementary dietary support alongside existing treatment.
Moving Toward More Targeted Gut Health Support
IBD- and IBS-related dietary support represent distinct development opportunities within the broader gut health category. Progress depends on connecting a clearly defined population with relevant research and a practical nutritional approach.
Symbiota™ 020 reflects MICROBIO’s commitment to extending microbiome innovation beyond everyday wellness. Its RESET approach and emerging UC research provide a direction for exploring more targeted support for fragile guts.
Meet MICROBIO at SupplySide Global 2026
We’ll be at the upcoming SupplySide Global in Las Vegas, October 28–30, 2026, at Booth 729, Level 2.
Meet our team to explore Symbiota™ 020, discuss the research behind our RESET Your Microbiome approach, and discover opportunities for ingredient and finished-product development.
[Schedule a Meeting with MICROBIO]
References
- Centers for Disease Control and Prevention. IBD Facts and Stats.
https://www.cdc.gov/inflammatory-bowel-disease/php/facts-stats/index.html - Sperber AD, et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2021;160:99–114.e3.
https://pubmed.ncbi.nlm.nih.gov/32294476/
